Loading clinical trials...
Loading clinical trials...
Open-Label Extension Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Patients With HoFH and HeFH, CVD, or at High Risk for CVD, on Stable Lipid-Lowering Therapy Requiring Additional LDL-C Reduction
Conditions
Interventions
lerodalcibep
Locations
12
United States
NorthShore University Health System
Evanston, Illinois, United States
Sterling Research Group
Cincinnati, Ohio, United States
The Lindner Research Center
Cincinnati, Ohio, United States
Metabolic & Atherosclerosis Research Center (MARC)
Cincinnati, Ohio, United States
G.B. Pant Institute of Postgraduate Medical Education & Research
New Delhi, India
Department of Medicine, Hadassah University Hospital
Jerusalem, Israel
Start Date
December 3, 2020
Primary Completion Date
July 30, 2025
Completion Date
December 31, 2025
Last Updated
October 22, 2024
NCT07473960
NCT07489209
NCT07037771
NCT07058077
NCT06331195
NCT06597019
Lead Sponsor
LIB Therapeutics LLC
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions